David A. Metcalfe - Nov 1, 2022 Form 4 Insider Report for NEXTGEN HEALTHCARE, INC. (NXGN)

Role
Chief Technology Officer
Signature
/s/ Jeffrey D. Linton, Attorney-in-Fact for David A. Metcalfe
Stock symbol
NXGN
Transactions as of
Nov 1, 2022
Transactions value $
-$189,720
Form type
4
Date filed
11/2/2022, 05:08 PM
Previous filing
Nov 1, 2022
Next filing
Nov 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NXGN Common Stock Options Exercise $250K +17.6K +9.85% $14.20 197K Nov 1, 2022 Direct F1
transaction NXGN Common Stock Options Exercise $207K +14.7K +7.5% $14.07 211K Nov 1, 2022 Direct F1
transaction NXGN Common Stock Sale -$647K -32.4K -15.32% $20.00 179K Nov 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXGN Stock Option (right to buy) Options Exercise $0 -17.6K -14.99% $0.00 100K Nov 1, 2022 Common Stock 17.6K $14.20 Direct F3
transaction NXGN Stock Option (right to buy) Options Exercise $0 -14.7K -12.05% $0.00 108K Nov 1, 2022 Common Stock 14.7K $14.07 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
F3 Original grant of 200,000 options granted on 2/1/2016 vested in four equal, annual installments beginning 2/1/2017.
F4 Original grant of 140,000 options granted on 10/31/2017 vested in four equal, annual installments beginning 10/31/2018.